Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP, Research & CSO | August 09, 2022 | August 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date August 09, 2022 · Filed August 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,500 |
Ending reported balance
After 2022-08-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-09 · Exercise / conversion · Acquired 70,177 · Balance 254,584 Row 2 · 2022-08-09 · Exercise / conversion · Acquired 7,916 · Balance 262,500 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 · Expires 2028-01-26 | Direct | 140,328 |
Reported balance
After 2022-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-09 · Exercise / conversion · Disposed 70,177 · Balance 140,328 F1: The option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.40 · Expires 2029-07-12 | Direct | 125,416 |
Reported balance
After 2022-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-09 · Exercise / conversion · Disposed 7,916 · Balance 125,416 F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable.
F2: 1/4 of the shares subject to the stock option vested and become exercisable on July 12, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2021 Filed Apr 15, 2021 21:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,560 | $1.53 | $8,506.80 |
DisclosureSEC source: 0001209191-21-026858 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-026392 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,555 Underlying: Common Stock · 14,000 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| April 09, 2021 Filed Apr 13, 2021 00:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 14,000 | $1.53 | $21,420.00 |
DisclosureSEC source: 0001209191-21-026392 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-023061 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,555 Underlying: Common Stock · 7,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $53.60 | $423,407.61 |
DisclosureSEC source: 0001209191-21-023061 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.5493 to $53.5769 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:26 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,900 | $1.53 | $12,087.00 |
DisclosureSEC source: 0001209191-21-023061 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:28 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-020165 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,455 Underlying: Common Stock · 2,340 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:28 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,340 | $48.00 | $112,320.00 |
DisclosureSEC source: 0001209191-21-020165 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 21:28 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,340 | $1.53 | $3,580.20 |
DisclosureSEC source: 0001209191-21-020165 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,560 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-019521 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,795 Underlying: Common Stock · 5,560 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,560 | $44.80 | $249,086.33 |
DisclosureSEC source: 0001209191-21-019521 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.7903 to $44.8095 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 21:58 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,560 | $1.53 | $8,506.80 |
DisclosureSEC source: 0001209191-21-019521 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 21:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-014320 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,355 Underlying: Common Stock · 18,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 21:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $63.74 | $503,576.81 |
DisclosureSEC source: 0001209191-21-014320 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.6761 to $63.8473 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 21:25 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 18,900 | $1.53 | $28,917.00 |
DisclosureSEC source: 0001209191-21-014320 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $67.38 | $0.00 |
DisclosureSEC source: 0001209191-21-011918 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:01 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-011918 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,200 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-009258 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,255 Underlying: Common Stock · 7,900 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,900 | $71.16 | $562,160.84 |
DisclosureSEC source: 0001209191-21-009258 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.0431 to $71.3903 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 21:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,900 | $1.53 | $12,087.00 |
DisclosureSEC source: 0001209191-21-009258 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 23:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,300 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-005745 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,155 Underlying: Common Stock · 31,300 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 23:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 31,300 | $48.17 | $1,507,805.51 |
DisclosureSEC source: 0001209191-21-005745 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.9959 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 23:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 31,300 | $1.53 | $47,889.00 |
DisclosureSEC source: 0001209191-21-005745 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,530 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-004048 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,455 Underlying: Common Stock · 10,530 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 10,530 | $38.00 | $400,140.00 |
DisclosureSEC source: 0001209191-21-004048 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,530 | $1.53 | $16,110.90 |
DisclosureSEC source: 0001209191-21-004048 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,730 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 23:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-21-003465 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,985 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 23:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $29.36 | $111,696.16 |
DisclosureSEC source: 0001209191-21-003465 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.9335 to $30.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 23:38 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-21-003465 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 23:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-065247 · doc4.xml · derivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,790 Underlying: Common Stock · 9,500 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 23:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 9,500 | $1.53 | $14,535.00 |
DisclosureSEC source: 0001209191-20-065247 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:06 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-065068 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,290 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:06 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $31.19 | $118,682.52 |
DisclosureSEC source: 0001209191-20-065068 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.1508 to $31.2380 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 23:06 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-065068 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-062738 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,095 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $31.27 | $118,965.61 |
DisclosureSEC source: 0001209191-20-062738 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.2482 to $31.2858 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-062738 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:02 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,930 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-060968 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,900 Underlying: Common Stock · 2,930 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:02 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,930 | $30.00 | $87,900.00 |
DisclosureSEC source: 0001209191-20-060968 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| November 27, 2020 Filed Dec 2, 2020 00:02 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,930 | $1.53 | $4,482.90 |
DisclosureSEC source: 0001209191-20-060968 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-060538 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,830 Underlying: Common Stock · 2,340 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,340 | $27.29 | $63,848.07 |
DisclosureSEC source: 0001209191-20-060538 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. 1,170 shares were sold at $27.2853 and 1,170 shares were sold at $27.2856. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,340 | $1.53 | $3,580.20 |
DisclosureSEC source: 0001209191-20-060538 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,340 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-058002 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,170 Underlying: Common Stock · 2,340 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 2,340 | $26.26 | $61,448.40 |
DisclosureSEC source: 0001209191-20-058002 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,340 | $1.53 | $3,580.20 |
DisclosureSEC source: 0001209191-20-058002 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 23:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,805 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-056143 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,510 Underlying: Common Stock · 3,805 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 23:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 3,805 | $35.04 | $133,334.81 |
DisclosureSEC source: 0001209191-20-056143 · doc4.xml · nonDerivative · entry 2 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0337 to $35.0481, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| October 27, 2020 Filed Oct 28, 2020 23:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 3,805 | $1.53 | $5,821.65 |
DisclosureSEC source: 0001209191-20-056143 · doc4.xml · nonDerivative · entry 1 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 22:33 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,560 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-054833 · doc4.xml · derivative · entry 3 Virgin Herbert · CIK 0001786378 · EVP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,315 Underlying: Common Stock · 5,560 shares Expires 2028-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.